Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

OBJECTIVE: Obesity and type 2 diabetes mellitus (T2DM) are risk factors for nonalcoholic fatty liver disease, including nonalcoholic steatohepatitis. This study assessed pegbelfermin (BMS‐986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM pred...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles, Edgar D., Neuschwander‐Tetri, Brent A., Pablo Frias, Juan, Kundu, Sudeep, Luo, Yi, Tirucherai, Giridhar S., Christian, Rose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587787/
https://www.ncbi.nlm.nih.gov/pubmed/30520566
http://dx.doi.org/10.1002/oby.22344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587787/
https://www.ncbi.nlm.nih.gov/pubmed/30520566
http://dx.doi.org/10.1002/oby.22344

Ejemplares similares